Next Article in Journal
Special Issue: “The Latest Clinical Advances in Thrombocytopenia”
Next Article in Special Issue
Myeloid-Derived Suppressor Cells (MDSCs) in Haematology
Previous Article in Journal
The Global Limb Anatomic Staging System (GLASS) for CLTI: Improving Inter-Observer Agreement
Previous Article in Special Issue
MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
Review

Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies

1
Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece
2
Laboratory of Haematology, Division of Laboratory Medicine, Medical School, University of Crete, 71003 Heraklion, Greece
3
Department of Laboratory Haematology, University Hospital of Heraklion, 71500 Heraklion, Greece
*
Authors to whom correspondence should be addressed.
Academic Editor: Helen A. Papadaki
J. Clin. Med. 2021, 10(16), 3462; https://doi.org/10.3390/jcm10163462
Received: 10 June 2021 / Revised: 21 July 2021 / Accepted: 22 July 2021 / Published: 4 August 2021
(This article belongs to the Special Issue Myeloid-Derived Suppressor Cells (MDSCs) in Haematology)
Myeloid-derived suppressor cells (MDSCs) are immature myeloid precursors which emerged as a potent regulator of the immune system, exerting suppressive properties in diverse disease settings. In regards to cancer, MDSCs have an established role in solid tumors; however, their contribution to immune regulation during hematologic malignancies and particularly in lymphomas remains ill-defined. Herein focused on lymphoma, we discuss the literature on MDSC cells in all histologic types, and we also refer to lessons learned by animal models of lymphoma. Furthermore, we elaborate on future directions and unmet needs and challenges in the MDSC field related to lymphoma malignancies which may shed light on the complex nature of the immune system in malignancies. View Full-Text
Keywords: Myeloid-derived suppressor cells; lymphomas; immune regulation Myeloid-derived suppressor cells; lymphomas; immune regulation
Show Figures

Figure 1

MDPI and ACS Style

Papafragkos, I.; Markaki, E.; Kalpadakis, C.; Verginis, P. Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies. J. Clin. Med. 2021, 10, 3462. https://doi.org/10.3390/jcm10163462

AMA Style

Papafragkos I, Markaki E, Kalpadakis C, Verginis P. Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies. Journal of Clinical Medicine. 2021; 10(16):3462. https://doi.org/10.3390/jcm10163462

Chicago/Turabian Style

Papafragkos, Iosif, Efrosyni Markaki, Christina Kalpadakis, and Panayotis Verginis. 2021. "Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies" Journal of Clinical Medicine 10, no. 16: 3462. https://doi.org/10.3390/jcm10163462

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop